Please ensure Javascript is enabled for purposes of website accessibility

Without a Vaccine, Is Merck Still a Hot COVID Stock?

By Alexander Carchidi - Jan 29, 2021 at 6:22AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With its vaccine projects terminated, Merck needs its coronavirus therapeutics to pull through.

Setbacks in clinical research happen all the time in the pharmaceutical industry, but that doesn't stop them from being disappointing for investors and patients alike. As of Monday, Merck (MRK 1.23%) stopped work on both of its coronavirus vaccine candidates after they failed to produce favorable results in early-stage clinical testing. While its candidates appeared to be safe, neither was capable of producing stronger immunity than what follows a coronavirus infection.

Given that its coronavirus vaccine programs were initiated with remarkably little fanfare and long after those of major competitors like Pfizer, investors may be bristling at the company's recent lukewarm performance. But its stock only took a small hit in the aftermath of the news, and it still has a pair of therapies for COVID-19 in development. Will these two treatments be enough to drive growth for shareholders, or is its future position in the market for coronavirus products too tenuous to bet on?

A scientist sits in front of a microscope near a rack of test tubes, face covered.

Image source: Getty Images.

Details on Merck's antiviral are sketchy

With its vaccines out of the picture, Merck still has two coronavirus projects in the works: MK-4482, an antiviral, and MK-7110, an anti-inflammatory. MK-4482 is being developed in conjunction with an outside collaborator, Ridgeback Biotherapeutics. Merck made a deal to acquire OncoImmune, the biotech that was previously working on MK-7110, in November.

So far, information on MK-4482's safety and efficacy is scarce. The drug is intended to prevent recently infected and symptomatic patients from worsening, thereby potentially preventing lengthy hospitalizations. If it gets approved, it might be a direct competitor to Gilead Sciences' antiviral remdesivir, which earned the company $873 million in the third quarter alone.

Even with a ballpark estimate for the potential revenue in view, investors have few clues about how the project is going. Management has explicitly stated that it prefers not to provide a regular drip of updates from the program unless there is something concrete to report. Nonetheless, Merck indicated that it could give an update on the drug's efficacy sometime in the first quarter, but the combined phase 2/3 clinical trial won't conclude until May.

Merck's coronavirus saga is just beginning

For all of the uncertainty surrounding its antiviral project, Merck may well have a winner on its hands with its novel anti-inflammatory therapy, MK-7110. In short, this could be the drug that doctors desperately need to save patients who are hospitalized and severely ill with COVID-19. According to an interim analysis of the phase 3 clinical trial data, patients treated with MK-7110 had a 50% lower risk of death or respiratory failure compared to those given a placebo. That's an extremely promising finding, and full results from the trial are expected sometime this quarter.

Shareholders should be excited, especially because development efforts have already led to revenue. Late last year, the U.S. government agreed to pay as much as $356 million for up to 100,000 doses of MK-7110, set to be delivered in the middle of 2021 if the drug is approved for sale. That's peanuts compared to Merck's trailing-12-month revenue of $47.35 billion, but it could be just the start.

If the U.S. Food and Drug Administration (FDA) gives the company the green light, it's highly likely that global interest in the drug will rise, leading to further purchasing activity. It's reasonable to expect that the stock could get a bump both with the FDA's announcement and then again when it reports its new revenue from sales later in the year.

In summary, there's still a lot to look forward to even without the two vaccine candidates in play. If you're considering an investment in Merck or another major pharmaceutical company, keep an eye out for any announcements of clinical trial data. While the stock is unlikely to surge anytime soon, investors should interpret increasing media coverage and positive early trial data as good signs.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$93.13 (1.23%) $1.13
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$51.59 (3.00%) $1.50
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$63.08 (0.80%) $0.50

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.